The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer

Breast Cancer Research and Treatment

Volumn 125, Issue 2, 2011, Pages 441-446

  Van Londen, G J ^a   Perera, S ^a   Vujevich, K ^a   Rastogi, P ^a   Lembersky, B ^a   Brufsky, A ^a   Vogel, V ^b   Greenspan, S L ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b GEISINGER MEDICAL CENTER   (United States)

Author keywords

Aromatase inhibitors; Body composition; Breast cancer; Gonadal hormones

Indexed keywords

ANASTROZOLE; ESTRADIOL; EXEMESTANE; LETROZOLE; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADJUVANT THERAPY; ADULT; ARTICLE; BODY COMPOSITION; BODY FAT; BREAST CANCER; CONTROLLED STUDY; DRUG RESPONSE; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; POSTMENOPAUSE; PRIORITY JOURNAL; SEX HORMONE DETERMINATION; WEIGHT GAIN;

ADIPOSE TISSUE; AROMATASE INHIBITORS; BODY COMPOSITION; BODY MASS INDEX; BONE DENSITY; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; ETIDRONIC ACID; FEMALE; GONADAL HORMONES; HUMANS; MIDDLE AGED; PLACEBOS; POSTMENOPAUSE; SEX HORMONE-BINDING GLOBULIN;

EID: 78650979007     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-1223-2     Document Type: Article

References (31)

1. LK Dunnwald MA Rossing CI Li 2007 Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients Breast Cancer Res 9 1 R6 10.1186/bcr1639 17239243 (Pubitemid 350215155)
2. IE Smith M Dowsett 2003 Aromatase inhibitors in breast cancer N Engl J Med 348 24 2431 2442 1:CAS:528:DC%2BD3sXksFKguro%3D 10.1056/NEJMra023246 12802030 (Pubitemid 36682823)
3. M Dowsett J Cuzick J Ingle A Coates J Forbes J Bliss M Buyse M Baum A Buzdar M Colleoni, et al. 2010 Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen J Clin Oncol 28 3 509 518 1:CAS:528:DC%2BC3cXivFartbk%3D 10.1200/JCO.2009.23.1274 19949017
4. MC Carr 2003 The emergence of the metabolic syndrome with menopause J Clin Endocrinol Metab 88 6 2404 2411 1:CAS:528:DC%2BD3sXkslCktb0%3D 10.1210/jc.2003-030242 12788835
5. SL Greenspan A Brufsky BC Lembersky R Bhattacharya KT Vujevich S Perera SM Sereika VG Vogel 2008 Risedronate prevents bone loss in breast cancer survivors: a 2-year, randomized, double-blind, placebo-controlled clinical trial J Clin Oncol 26 16 2644 2652 1:CAS:528:DC%2BD1cXnvVOhsL8%3D 10.1200/JCO.2007.15.2967 18427147
6. T Fuerst HK Genant 1996 Evaluation of body compositlon and total bone mass with the hologic QDR 4500 Osteo Int 6 Suppl 1 203
7. CC Lee JZ Kasa-Vubu MA Supiano 2003 Differential effects of raloxifene and estrogen on insulin sensitivity in postmenopausal women J Am Geriatr Soc 51 5 683 688 10.1034/j.1600-0579.2003.00214.x 12752845 (Pubitemid 36541434)
8. CM Francucci P Daniele N Iori A Camilletti F Massi M Boscaro 2005 Effects of raloxifene on body fat distribution and lipid profile in healthy post-menopausal women J Endocrinol Invest 28 7 623 631 1:CAS:528: DC%2BD2MXhtFeksb7K 16218045
9. GA Tommaselli C Di Carlo A Di Spiezio Sardo G Bifulco D Cirillo M Guida R Capasso C Nappi 2006 Serum leptin levels and body composition in postmenopausal women treated with tibolone and raloxifene Menopause 13 4 660 668 10.1097/01.gme.0000227335.27996.d8 16837888 (Pubitemid 44079536)
10. DE Jacobsen MM Samson YT Schouw DE Grobbee HJ Verhaar 2008 Efficacy of tibolone and raloxifene for the maintenance of skeletal muscle strength, bone mineral density, balance, body composition, cognitive function, mood/depression, anxiety and quality of life/well-being in late postmenopausal women >/=70 years: study design of a randomized, double-blind, double-dummy, placebo-controlled, single-center trial Trials 9 32 10.1186/1745-6215-9-32 18533987 (Pubitemid 351858945)
11. MC Nguyen RB Stewart MA Banerji DH Gordon JG Kral 2001 Relationships between tamoxifen use, liver fat and body fat distribution in women with breast cancer Int J Obes Relat Metab Disord 25 2 296 298 1:CAS:528:DC%2BD3MXhsFWqu70%3D 10.1038/sj.ijo.0801488 11410835
12. A Grey J Stapleton M Evans I Reid 1995 The effect of the anti-estrogen tamoxifen on cardiovascular risk factors in normal postmenopausal women J Clin Endocrinol Metab 80 11 3191 3195 1:CAS:528:DyaK2MXptleitbo%3D 10.1210/jc.80.11.3191 7593425
13. G Francini R Petrioli A Montagnani A Cadirni S Campagna E Francini S Gonnelli 2006 Exemestane after tamoxifen as adjuvant hormonal therapy in postmenopausal women with breast cancer: effects on body composition and lipids Br J Cancer 95 2 153 158 1:CAS:528:DC%2BD28XmvFajsbc%3D 10.1038/sj.bjc.6603258 16835585 (Pubitemid 44050914)
14. DL Enns PM Tiidus 2010 The influence of estrogen on skeletal muscle: sex matters Sports Med 40 1 41 58 10.2165/11319760-000000000-00000 20020786
15. RA Yates M Dowsett GV Fisher A Selen PJ Wyld 1996 Arimidex (ZD1033): a selective, potent inhibitor of aromatase in postmenopausal female volunteers Br J Cancer 73 4 543 548 1:CAS:528:DyaK28Xhs1Kjt7o%3D 8595172
16. E Bajetta N Zilembo M Dowsett L Guillevin A Di Leo L Celio A Martinetti A Marchiano P Pozzi S Stani, et al. 1999 Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients Eur J Cancer 35 2 208 213 1:CAS:528:DyaK1MXisVagtbw%3D 10.1016/S0959-8049(98)00392-X 10448261 (Pubitemid 29136769)
17. S Bhasin L Woodhouse TW Storer 2001 Proof of the effect of testosterone on skeletal muscle J Endocrinol 170 1 27 38 1:CAS:528:DC%2BD3MXltlalu7s%3D 10.1677/joe.0.1700027 11431134 (Pubitemid 32677563)
18. KK Miller 2009 Androgen deficiency: effects on body composition Pituitary 12 2 116 124 1:CAS:528:DC%2BD1MXjslWmurY%3D 10.1007/s11102-008-0121-7 18421580
19. S Ling PA Komesaroff K Sudhir 2009 Cardiovascular physiology of androgens and androgen testosterone therapy in postmenopausal women Endocr Metab Immune Disord Drug Targets 9 1 29 37 1:CAS:528:DC%2BD1MXks1Cnt70%3D 10.2174/187153009787582414 19275679
20. JI Torrens K Sutton-Tyrrell X Zhao K Matthews S Brockwell M Sowers N Santoro 2009 Relative androgen excess during the menopausal transition predicts incident metabolic syndrome in midlife women: study of Women's Health Across the Nation Menopause 16 2 257 264 10.1097/gme.0b013e318185e249 18971793
21. I Janssen LH Powell S Crawford B Lasley K Sutton-Tyrrell 2008 Menopause and the metabolic syndrome: the Study of Women's Health Across the Nation Arch Intern Med 168 14 1568 1575 1:CAS:528:DC%2BD1cXpvFKjsb4%3D 10.1001/archinte.168. 14.1568 18663170
22. EL Ding Y Song JE Manson DJ Hunter CC Lee N Rifai JE Buring JM Gaziano S Liu 2009 Sex hormone-binding globulin and risk of type 2 diabetes in women and men N Engl J Med 361 12 1152 1163 1:CAS:528:DC%2BD1MXhtFOjsLnO 10.1056/NEJMoa0804381 19657112
23. JR Perry MN Weedon C Langenberg AU Jackson V Lyssenko T Sparso G Thorleifsson H Grallert L Ferrucci M Maggio, et al. 2010 Genetic evidence that raised sex hormone binding globulin (SHBG) levels reduce the risk of type 2 diabetes Hum Mol Genet 19 3 535 544 1:CAS:528:DC%2BC3cXotlej 10.1093/hmg/ddp522 19933169
24. H Abdulhaq C Geyer 2008 Safety of adjuvant endocrine therapy in postmenopausal women with breast cancer Am J Clin Oncol 31 6 595 605 1:CAS:528:DC%2BD1cXhsVKnurbL 10.1097/COC.0b013e31816d9171 19060594
25. MS Ewer S Gluck 2009 A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health Cancer 115 9 1813 1826 1:CAS:528: DC%2BD1MXlt1ygu74%3D 10.1002/cncr.24219 19235248
26. S Gandhi S Verma 2007 Aromatase inhibitors and cardiac toxicity: getting to the heart of the matter Breast Cancer Res Treat 106 1 1 9 1:CAS:528:DC%2BD2sXhtFSmu7rE 10.1007/s10549-006-9470-y 17211535 (Pubitemid 47498087)
27. S Lewis 2007 Do endocrine treatments for breast cancer have a negative impact on lipid profiles and cardiovascular risk in postmenopausal women? Am Heart J 153 2 182 188 1:CAS:528:DC%2BD2sXntlGqsQ%3D%3D 10.1016/j.ahj.2006.10.034 17239675 (Pubitemid 46096865)
28. B Seruga IF Tannock 2009 Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes J Clin Oncol 27 6 840 842 10.1200/JCO.2008.19.5594 19139426
29. I Janssen LH Powell R Kazlauskaite SA Dugan 2009 Testosterone and visceral fat in midlife women: the Study of Women's Health Across the Nation (SWAN) fat patterning study Obesity 18 3 604 610 10.1038/oby.2009.251 19696765
30. D Jacobsen M Samson M Emmelot H Verhaar 2009 Raloxifene and body composition and muscle strength in postmenopausal women: a randomized, double-blind, placebo-controlled trial Eur J Endocrinol 162 371 376 10.1530/EJE-09-0619 19884264
31. RJ Santen H Brodie ER Simpson PK Siiteri A Brodie 2010 History of aromatase: saga of an important biological mediator and therapeutic target Endocr Rev 30 4 343 375 10.1210/er.2008-0016